Patent · US Active

Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors

US9284317B2 · kind B2 · utility

1Cited by

0References

10Claims

0Family size

Assignee

Bayer Intellectual Property GmbH · DE

Inventors

Marcus Koppitz · Berlin, DE
Ulrich Klar · Berlin, DE
Rolf Jautelat · Haan, DE
Dirk Kosemund · Berlin, DE
Rolf Bohlmann · Berlin, DE
Benjamin Bader · Berlin, DE
Philip Lienau · Berlin, DE
Gerhard Siemeister · Berlin, DE

Key dates

Filing date	Dec 13, 2011
Grant date	Mar 15, 2016
Priority date	—
Expiry date	Dec 13, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted imidazopyrazine compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.